赛生药业2023年报

(Incorporated in the Cayman Islands with limited liability)( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) 股份代號Stock Code: 6600 2023年 度 報告Annual Report Content Corporate information2Chairman’s statement4Management discussion and analysis22Biographies of director and senior management31Corporate governance report40Directors’ report60Independent auditor’s report94Consolidated statement of comprehensive income102Consolidated balance sheet104Consolidated statement of changes in equity106Consolidated statement of cash flows108Notes to the consolidated financial statements110Financial summary226Environmental, Social and Governance Report227Definitions and glossary252 Corporate Information BOARD OF DIRECTORS Executive Directors Mr. Zhao Hong(Chief Executive Officer and President)Ms. Pan Rongrong(Chief Financial Officer and Vice President) Non-executive Directors Li ZhenfuDaniel Luzius VasellaLin Shirley Yi-Hsien Mr. Li Zhenfu(Chairman)Dr. Daniel Luzius VasellaMs. Lin Shirley Yi-HsienMs. Wang Haixia Independent Non-executive Directors Chen PingGu Alex YushaoWendy Hayes Dr. Liu GuoenDr. Chen PingMr. Gu Alex YushaoMs. Wendy Hayes AUDIT COMMITTEE Wendy HayesLin Shirley Yi-HsienGu Alex Yushao Ms. Wendy Hayes(Chairwoman)Ms. Lin Shirley Yi-HsienMr. Gu Alex Yushao REMUNERATION COMMITTEE Gu Alex YushaoChen Ping Mr. Gu Alex Yushao(Chairman)Mr. Zhao HongDr. Chen Ping NOMINATION COMMITTEE Li ZhenfuWendy Hayes Mr. Li Zhenfu(Chairman)Ms. Wendy HayesDr. Liu Guoen COMPANY SECRETARY 2024328 Ms. Pan RongrongMs. Chan Sin Man Nico (Resigned on March 28, 2024) AUTHORISED REPRESENTATIVES Mr. Zhao HongMs. Pan Rongrong AUDITOR PricewaterhouseCoopers REGISTERED OFFICE PO Box 309, Ugland HouseGrand Cayman, KY1-1104Cayman Islands PO Box 309,Ugland HouseGrand CaymanKY1-1104Cayman Islands HEAD OFFICE AND PRINCIPAL PLACE IN THE PRC 38122 22/F, Central Plaza381 Middle Huaihai Road, ShanghaiPRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG 3113401A 3401A, Windsor House311 Gloucester Road, Causeway BayHong Kong PRINCIPAL SHARE REGISTRAR Maples Fund Services (Cayman) LimitedPO Box 1093, Boundary Hall, Cricket SquareGrand Cayman, KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedPO Box 1093, Boundary Hall, Cricket SquareGrand Cayman, KY1-1102Cayman Islands HONG KONG SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong HONG KONG LEGAL ADVISER Clifford Chance PRINCIPAL BANKS China Minsheng Banking Corp., Ltd. Hong Kong BranchCitibank N.A., Hong Kong BranchBank of China (Hong Kong) Limited www.sciclone.com WEBSITEwww.sciclone.com 6600 STOCK CODE6600 Chairman’s Statement I. I. Message from our Chairman 2023 Lookingback at 2023,the impact of the COVID-19 pandemic has graduallysubsided, but the global economy was still struggling to find its way forwardagainstthe backdrop of geopolitical conflicts,inflation and weak recovery.Despite a complex and volatile business environment last year, SciClone rose tothe challenge and took multiple measures to maintain the steady development ofthe Company’s core business, continue to bring high-quality products to patients,and set a benchmark of excellence in the industry. 20232023OrserduVaboremIII Under the outstanding leadership of our chief executive officer, Mr. Zhao Hong,our team was fearless in the face of challenges and worked together to achieverapid growth in the Company’s performance in 2023 and delivered gratifyingresults.The Company’s core product,Zadaxin,seized market opportunities in2023 and continues to benefit a wide range of patients, while the Company’sin-licensedproduct,Danyelza,officially launched in China,further expandingSciClone’s product portfolio. In 2023, SciClone also obtained the exclusive licenseto develop and commercialize another innovative product Orserdu in China. ThePhase III clinical trial of the new antimicrobial product Vaborem completed patientenrolment. A series of pipeline products have made positive progress, bringingnew momentum to the Company’s future development. 20217212022 Since the Hong Kong stock market plunged in July 2021, the market has entereda prolonged downturn, with investor pessimism pervading and fear dominating,a sharp contrast to pre-2021. Although SciClone has consistently achieved steadygrowth since its IPO, the Company’s share price performance has long failed tofullyreflect the Company’s value and fundamentals.The unsatisfactory shareprice has on the one hand, limited the Company’s ability to refinance or considerM&A in the capital markets, and on the other hand, affected the Company’sbusinessoperations and the implementation of its long-term strategies.As Imentioned in the my letter to shareholders in 2022, the Company has alwaysbeencommitted to identifying innovative products with first-in-class or best-in-classpotential to boost future performance growth momentum.In thecurrent challenging operating environment, the Company has had to proactivelyimple